Head-To-Head Contrast: Cyclerion Therapeutics (NASDAQ:CYCN) & scPharmaceuticals (NASDAQ:SCPH)

Cyclerion Therapeutics (NASDAQ:CYCN) and scPharmaceuticals (NASDAQ:SCPH) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.

Analyst Recommendations

This is a summary of recent ratings for Cyclerion Therapeutics and scPharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclerion Therapeutics	0	0	0	0	0.00
scPharmaceuticals	0	0	2	0	3.00

scPharmaceuticals has a consensus target price of $15.00, suggesting a potential upside of 370.22%. Given scPharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe scPharmaceuticals is more favorable than Cyclerion Therapeutics.

Insider and Institutional Ownership

75.6% of Cyclerion Therapeutics shares are held by institutional investors. Comparatively, 89.5% of scPharmaceuticals shares are held by institutional investors. 36.1% of Cyclerion Therapeutics shares are held by company insiders. Comparatively, 5.5% of scPharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Cyclerion Therapeutics has a beta of 1.87, indicating that its share price is 87% more volatile than the S&P 500. Comparatively, scPharmaceuticals has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500.

Earnings & Valuation

This table compares Cyclerion Therapeutics and scPharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclerion Therapeutics	$194,000.00	47.91	-$5.26 million	N/A	N/A
scPharmaceuticals	$13.59 million	11.75	-$54.81 million	($1.90)	-1.68

Cyclerion Therapeutics has higher earnings, but lower revenue than scPharmaceuticals.

Profitability

This table compares Cyclerion Therapeutics and scPharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cyclerion Therapeutics	N/A	-55.32%	-48.35%
scPharmaceuticals	-264.60%	-244.93%	-68.56%

Summary

Cyclerion Therapeutics beats scPharmaceuticals on 7 of the 12 factors compared between the two stocks.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

About scPharmaceuticals

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.